Streetbeat News

LQDA

Liquidia Corporation

https://www.liquidia.com

Industry

Biotechnology

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

Open

10.66

Mkt cap

902M

Volume

656K

High

10.97

P/E Ratio

-6.85

52-wk high

16.99

Low

10.61

Div yield

N/A

52-wk low

6.06

Liquidia's stock price increased following the announcement of a $67.5 million capital raise through the sale of 6,460,674 common shares at $8.90 each.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2024 | 2:36 pm

Several stocks saw significant gains on Wednesday despite a general market downturn. Petco Health and Wellness (WOOF) rose 8.4% despite reporting larger-than-expected losses. PureCycle Technologies (PCT) jumped 20% following a financing announcement. Sigma Lithium (SGML), Lithium Americas (LAAC), and Albemarle (ALB) gained due to a rise in lithium prices. Hyliion Holdings (HYLN) rose after securing a Navy contract. Dave & Buster’s (PLAY) increased after better-than-expected earnings. AppLovin (APP) gained following a price target increase by B of A Securities.

Portfolio Pulse from Avi Kapoor

September 11, 2024 | 2:19 pm

Liquidia Corporation (NASDAQ:LQDA) has announced a $67.5 million raise through a public offering and private placement of common stock, alongside a $32.5 million advance from HealthCare Royalty. The funds will support the development of YUTREPIA and other projects.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2024 | 12:29 pm

HC Wainwright & Co. analyst Andrew Fein has reiterated a Buy rating for Liquidia (NASDAQ:LQDA) and maintained a price target of $29.

Portfolio Pulse from Benzinga Newsdesk

August 23, 2024 | 11:17 am

Needham analyst Serge Belanger has reiterated a Buy rating on Liquidia (NASDAQ:LQDA) and maintained a price target of $19.

Portfolio Pulse from Benzinga Newsdesk

August 22, 2024 | 4:02 pm

Liquidia has filed a lawsuit challenging the FDA's decision to grant 3-year exclusivity to Tyvaso DPI, delaying the final approval of its own drug, YUTREPIA, until May 2025.

Portfolio Pulse from Benzinga Newsdesk

August 22, 2024 | 10:05 am

Jim Cramer praised PayPal's CEO and recommended buying Flutter Entertainment due to its strong performance and potential growth with the football season. He expressed skepticism about Liquidia Corporation and Crown Castle, and advised selling AST SpaceMobile.

Portfolio Pulse from Avi Kapoor

August 21, 2024 | 1:23 pm

Liquidia Corporation (NASDAQ:LQDA) received tentative FDA approval for YUTREPIA, a treatment for pulmonary hypertension, but faces regulatory exclusivity challenges from United Therapeutics' Tyvaso DPI. Liquidia's stock fell 30.6% following the news, and analysts have lowered their price targets while maintaining Buy ratings.

Portfolio Pulse from Avi Kapoor

August 20, 2024 | 12:15 pm

Top Wall Street analysts have updated their price targets and ratings for several companies, including Palo Alto Networks, Fabrinet, Estée Lauder, Liquidia, Snowflake, ZIM Integrated Shipping, Globant, Stride, BioMarin Pharmaceutical, and Hyatt Hotels. These changes reflect varying expectations for stock performance, with some companies seeing upgrades and others downgrades.

Portfolio Pulse from Avi Kapoor

August 20, 2024 | 11:53 am

BTIG analyst Julian Harrison maintains a Buy rating on Liquidia (NASDAQ:LQDA) but lowers the price target from $29 to $25.

Portfolio Pulse from Benzinga Newsdesk

August 20, 2024 | 11:47 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.